(COLL) Collegium Pharmaceutical, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(COLL) Collegium Pharmaceutical, Inc. Complete Analysis Pack
See the Bigger Picture
This Collegium Pharmaceutical, Inc. BCG Matrix is a ready-made strategic analysis that helps you see how the company’s products or business units fit into Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the actual report content, so you can review the format and quality before buying. Purchase the full version to get the complete ready-to-use analysis.
Stars
BELBUCA
BELBUCA is Collegium Pharmaceutical's buprenorphine buccal film for severe chronic pain, and its branded specialty niche supports repeat prescribing and steady access. In 2024, Collegium reported net product revenues of about $750 million, with BELBUCA a core contributor alongside Xtampza ER. That profile fits a Star: strong demand, durable reimbursement, and room to keep growing.
Abuse-deterrent pain brand
Collegium Pharmaceutical, Inc.'s abuse-deterrent pain brand is a Star because its abuse-deterrent opioid therapy gives it a clear edge over plain generics. That protection supports premium pricing and helped the brand hold share in a mature, low-growth opioid market. With branded extended-release oxycodone still a niche category, differentiation matters more than broad market growth.
Chronic pain specialty segment
Collegium Pharmaceutical, Inc. stays tightly focused on pain management, led by Xtampza ER and Belbuca, so its chronic pain specialty segment has a sharper message and a narrower selling footprint than broad pharma peers. In a crowded opioid and non-opioid market, that focus can win share through deep provider targeting and repeat prescribing, which is why this segment fits the Stars profile if growth stays strong.
Branded prescription base
Collegium Pharmaceutical, Inc.’s Stars segment is its branded prescription base, led by Xtampza ER and Belbuca. Branded drugs usually earn better support from marketing, payer access, and field reps than commodity generics, so this mix fits a high-share, high-support growth profile. The result is stronger pricing control and more durable revenue than a generic-led model.
- Branded Rx drives most value.
- Access and promotion matter most.
- Mix supports premium economics.
Lifecycle management
Collegium Pharmaceutical, Inc. leans on 2 core pain brands, Xtampza ER and Belbuca, plus brand protection and payer access to extend cash flow as the pain market stays active. That is classic Star behavior: defend share first, then keep growing the asset base through lifecycle management.
- 2 branded pain assets drive the strategy
- Protection supports share retention
- Access helps sustain volume growth
- Lifecycle work extends asset value
Collegium’s Star Pain Brands Drive a $750M Revenue Engine
Collegium Pharmaceutical, Inc.'s Stars are Xtampza ER and BELBUCA, the two branded pain assets that drive repeat use, payer access, and premium pricing. In 2024, Collegium Pharmaceutical, Inc. reported about $750 million in net product revenues, showing the scale behind this high-share franchise.
| Metric | Value |
|---|---|
| Core Star brands | Xtampza ER, BELBUCA |
| 2024 net product revenues | ~$750 million |
| Key strength | Brand protection + access |
| Star logic | High share, durable demand |
What is included in the product
Detailed Word Document
Collegium Pharmaceutical’s BCG Matrix maps its products into Stars, Cash Cows, Question Marks, and Dogs for clear capital-allocation insight.
Editable Excel File
One-page BCG Matrix for Collegium Pharmaceutical, Inc. to spot business units fast and ease strategic decision-making
Reference Sources
Collegium Pharmaceutical, Inc. Reference Sources provide a credible trail for validating key claims and speeding confident decision-making.
Cash Cows
Xtampza ER
Xtampza ER is Collegium Pharmaceutical, Inc.'s flagship oxycodone ER brand and a classic cash cow: it serves persistent severe pain, has recurring demand, and benefits from mature branded use. In Collegium Pharmaceutical, Inc.'s latest annual reporting, Xtampza ER generated about $290 million in net sales, giving the company a steady, high-cash base.
1 core oxycodone ER platform
Collegium Pharmaceutical, Inc.'s core oxycodone ER platform is a classic cash cow: the franchise is mature, so promotion is lighter and more efficient than in launch mode. In FY2024, net product sales were about $700 million and adjusted EBITDA was about $320 million, showing strong cash generation. That fits a low-growth, high-share BCG cash-cow profile.
Established payer access
Collegium Pharmaceutical, Inc. has two core cash drivers, Xtampza ER and Belbuca, and both already sit on established payer and formulary access. That cuts new-market spend and lowers commercial friction, which helps convert sales into cash faster. In a Cash Cows role, that stable access is the key edge.
Repeat chronic pain scripts
Repeat chronic pain scripts fit a Cash Cow because patients often need ongoing therapy, so prescriptions can recur month after month. That repeat use lowers the cost to keep revenue coming in, which is why this business line can stay cash rich instead of cash hungry. Collegium Pharmaceutical, Inc. benefits most when refill rates stay steady and new-selling spend stays low.
- Recurring refills support steady revenue
- Lower incremental selling cost
- Predictable cash flow drives Cash Cow status
Branded opioid margins
Collegium Pharmaceutical, Inc.’s branded opioid portfolio fits the Cash Cows box: mature, low-growth, and still able to throw off cash. Branded specialty opioids usually earn better margins than generics, so once volume growth slows, profit quality matters more than expansion. Collegium’s established brands are built for this stage.
- High-margin branded sales
- Low-growth, steady cash
- More profit than expansion
Collegium's Cash Cow: Strong Refill Sales, Steady Cash Flow
Xtampza ER and Belbuca give Collegium Pharmaceutical, Inc. a mature, repeat-use base that fits the Cash Cow bucket. In FY2024, net product sales were about $700 million and adjusted EBITDA was about $320 million, so cash conversion stayed strong. Xtampza ER alone brought in about $290 million in net sales, showing the value of steady refill demand.
| Metric | FY2024 |
|---|---|
| Net product sales | About $700 million |
| Adjusted EBITDA | About $320 million |
| Xtampza ER net sales | About $290 million |
Get Your Copy
Collegium Pharmaceutical, Inc. Reference Sources
The Collegium Pharmaceutical, Inc. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No sample filler or hidden changes—just the full, ready-to-use report. Download it instantly and use it for analysis, presentations, or strategy planning. What you preview is what you get.
Dogs
Nucynta ER
Nucynta ER sits in the "Dogs" quadrant: it is an older tapentadol extended-release product in a mature opioid market, so growth is weak. Generic tapentadol ER competition and payer pressure keep share under strain, and by 2025 this profile fits a low-growth, low-share asset with limited upside for Collegium Pharmaceutical, Inc.
Nucynta IR
Nucynta IR is Collegium Pharmaceutical, Inc.’s immediate-release tapentadol product, and its BCG fit is a "Dog" because the IR pain market is crowded and price-driven. Immediate-release opioids and analgesics face heavy generic pressure, so differentiation is thin and growth is limited. That makes Nucynta IR a low-share, low-growth asset that likely deserves harvest-style management.
Tapentadol franchise
Nucynta, built on tapentadol chemistry, is a mature opioid franchise with limited room to expand in a crowded pain market. It does not have the same market-share momentum as Collegium Pharmaceutical, Inc.’s core growth brands, so it fits the Dogs bucket in a BCG Matrix. The franchise is mainly a cash-flow asset now, not a growth engine.
Generic competition
Generic competition is the classic dog for older pain brands: once patent or exclusivity protection fades, U.S. generic drugs can take over more than 90% of prescriptions, and price cuts can reach 70% to 90%. That wipes out pricing power fast, so both share and gross margin tend to shrink.
- Generic entry drives steep price cuts.
- Volume usually shifts to low-cost rivals.
- Margins compress after exclusivity ends.
Declining legacy revenue
Collegium Pharmaceutical, Inc.’s legacy pain brands fit "Dogs" because they face declining demand while newer products take share. In the latest reported full year, legacy net revenue fell as the company shifted focus to JOURNAVX, and heavy reinvestment in a shrinking base would not clear a good return bar. They are usually kept only for residual cash flow.
- Legacy revenue is shrinking
- Newer therapies get more attention
- Cash flow, not growth, is the case
Nucynta ER/IR: Mature, Generic-Pressured Cash Cows
Nucynta ER and Nucynta IR are Dogs for Collegium Pharmaceutical, Inc. because they sit in mature tapentadol markets with weak growth, heavy generic pressure, and thin pricing power. Once exclusivity fades, U.S. generics can take over more than 90% of prescriptions and cut prices 70% to 90%, so these brands now act mainly as residual cash-flow assets.
| Metric | Dog signal |
|---|---|
| Generic prescription share | >90% |
| Typical price drop | 70% to 90% |
| Growth outlook | Low |
| Share position | Weak |
Question Marks
New pain pipeline
Collegium Pharmaceutical, Inc. stays in the Question Mark box if its new pain pipeline cannot scale fast. In 2024, its business was still anchored by Xtampza ER and Belbuca, so any new pain asset starts with low share and must win adoption quickly. If launches lag, the pipeline burns cash and stays a question mark; if uptake accelerates, it can turn into a growth engine.
Label expansion
Label expansion can push Collegium Pharmaceutical, Inc.'s pain brands from steady cash flow to faster growth, but it is not cheap or quick. In pain, new label work can take 12-24 months, need clinical data, and can cost millions in study and sales spend, so the payoff is high but the risk is too.
Business development deals
Collegium Pharmaceutical, Inc. has built its portfolio through deals, including Nucynta in 2017, Belbuca in 2018, and Jornay PM in 2023. These licensed or acquired assets can drive growth, but each starts with low share, so they fit the BCG question-mark profile. The upside is real, but so is the risk: 2023 Jornay PM added scale fast, yet it still needs marketing and adoption to turn into a star.
Non-opioid opportunities
Collegium Pharmaceutical, Inc. has no marketed non-opioid pain drug yet, so this stays a Question Mark in the BCG Matrix. Non-opioid therapies could widen the portfolio beyond opioid revenue, but they need proof in trials and payer uptake before they can matter. The upside is a larger pain market; the risk is that most assets here are still unproven.
- Portfolio diversification, not yet revenue
- Big market, weak current validation
- High upside if adoption sticks
Adjacent CNS expansion
Collegium Pharmaceutical, Inc. has proved it can sell branded specialty CNS drugs, with its pain portfolio still driving cash flow. Adjacent CNS expansion could lift long-term growth if it reuses its commercial base and payer access.
But early moves into new CNS areas stay a Question Mark until share is proven. Without durable uptake, these bets can burn cash before they add scale.
- Strong specialty sales model
- Adjacency can extend growth
- Market share proof comes first
Collegium’s New Bets Need Fast Adoption to Pay Off
Collegium Pharmaceutical, Inc.’s Question Marks are new pain and CNS bets with low share, so they need fast uptake to justify spend. Deals like Jornay PM in 2023 and earlier pain assets show upside, but without proven adoption, these products stay cash hungry.
| Item | Signal |
|---|---|
| Jornay PM | Low-share growth bet |
| New pain assets | High risk, high upside |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.